Even folks with money and in high positions have problems getting access to cancer drugs, as you can read below, and this was not an issue of not being able to afford the medication. When you read items as such, it makes you stop and think how precious life and healthcare really is. BD ...
Posted to
The Medical Quack .... by Barbara Duck
on 10-31-2008
Filed under: Medically Related, Pharma/FDA News, Other Items of Interest, drugs, Cancer, Tysabri, Access to medications, Cancer Drugs, Fred Baron, Biogen
The UK continues to say “no” to cancer drugs due to price. If you stop and look at the prices for cancer drugs, something along the line here is going to need to balance soon. It is great and wonderful to have the R and D and great breakthroughs that are occurring almost daily, but what good does...
The costs of cancer treatment and associated drugs is rising as we all know. We are pouring money into R and D as fast as we can, and yes that does cost money, but insurers are making it hard to get insurance coverage and somewhere along the line you need to have a drug that is affordable as well...
This is probably a good move to speed this process up since many pharmaceutical companies have and are looking at moving more trials to India. More information can be read here about the changing face of Pharma in reference to research and development. One more area to think about too is the use...
Posted to
The Medical Quack .... by Barbara Duck
on 09-19-2008
Filed under: Medically Related, Pharma/FDA News, Genomics, drugs, Pharma, Cancer, clinical trials, Congress, DNA Testing, National Cancer Institute, Justice Department
Many of the generic manufacturers started years back with knock off drugs to sell locally in India, but now the game is changing to where US Pharma is using some of the talent, which costs less than R and D individuals here in the states, to further develop existing work, in other words somewhat continue...
Posted to
The Medical Quack .... by Barbara Duck
on 09-05-2008
Filed under: Medically Related, Pharma/FDA News, Genomics, drugs, Pharma, Biotech, Cancer, FDA, Budgets, R and D, Alzheimers, Outsourcing
This article brings up a good point, when a patient has no other choices and the potential of a new drug could offer some relief, what is the verdict at this point? The FDA has turned it's way of thinking around now to being much more conservative on the drugs that are approved. Do the drug companies...
The patent is stated not to expire until 2010 and this will put a 30 hold at the FDA to grant approval. This one should prove interesting to follow and see where the infringement occurs. BD LONDON -(Dow Jones)- Sanofi-Aventis SA (SNY) has launched a legal action against Canadian generic drugmaker...